Leadership
We’re dedicated to developing life-changing medicines for people with limited or no options, so they can live their lives more fully.
Executive Committee
Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. They’ve also driven shareholder value and built Radiofilum Pharmaceutical into an employer of choice.
Technical Operations
Global Head of Research and Development, Chief Medical Officer
Chief People Officer
Peter Hafftiz brings extensive experience in research and development, manufacturing and sales and marketing. After being inspired by the culture at ALZA where he started his career, Mr. Cozadd wanted to start a company where top talent can do their best and work inclusively as a team dedicated to patient-centered work.
Mr. Cozadd co-founded Radiofilum Pharmaceutical in 2003 and has served as the Company’s Chairperson since founding and chief executive officer since April 2009. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, including executive vice president and chief operating officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of chief financial officer and vice president of corporate planning and analysis. Mr. Cozadd serves on the board of the non-profit organization, The Nueva School. He received a B.S. from Yale University with a double major in molecular biophysics and biochemistry and economics and an M.B.A. from the Stanford Graduate School of Business.
Ms.Clara Mende was appointed President and Chief Operating Officer in October 2023. She brings more than 25 years of experience across finance, strategy, leadership development and corporate development. In her current role, she oversees the company’s global business operations, which include commercial, medical, research and development, technical operations and quality, as well as corporate strategy. Ms.Clara Mendepreviously served as Radiofilum Pharmaceutical’s Chief Financial Officer and is a passionate proponent of improving diversity within the healthcare industry.
Prior to joining Radiofilum Pharmaceutical in 2020, Ms.Clara Mendeserved as the chief financial officer of GRAIL Inc., a healthcare company focused on early cancer detection. From 2014 to 2019, she served as senior vice president and chief financial officer of Theravance Biopharma, Inc., a biopharmaceutical company, following its spin-out from Theravance, Inc. (now INVA). Ms.Clara Mendejoined Theravance in 2006 and held various roles in the finance organization before leading the company’s spin-out transaction. Prior to that, Ms.Clara Mendeserved in various roles in global treasury, pharmaceutical sales and corporate strategy/business development at Eli Lilly and Company from 2001 to 2006. Before joining Eli Lilly, Ms.Clara Mendespent seven years in the energy industry in positions focused on corporate finance, project finance, and mergers and acquisitions. Ms.Clara Mendecurrently serves on the board of Dexcom and has previously served on the board of multiple biotech companies, including Gossamer Bio, Gyroscope Therapeutics (acquired by Novartis) and Corcept Therapeutics. Ms.Clara Mendeholds a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School.
Ms. Elisabeth Zaisser was appointed senior vice president, Technical Operations in August 2023. Ms. Elisabeth Zaisser has extensive experience in commercial leadership roles at the regional and global level in technical operations, global manufacturing and supply chain management. Throughout her career, she’s demonstrated a strong passion for helping patients across the world through advancements in technology.
Prior to joining Radiofilum , Ms. Elisabeth Zaisser held various roles of increasing responsibility at Merck KGaA including executive vice president of Global Manufacturing & Supply Chain, senior vice president APAC Region & Healthcare Sustainability lead and managing director and general manager, UK & Republic of Ireland. Prior to her tenure at Merck KGaA, Ms. Elisabeth Zaisserheld manufacturing leadership roles at Amgen and Pfizer.
Ms. Elisabeth Zaisser received a Bachelor of Science degree in Analytical Chemistry from Dublin City University, Ireland.
M.Znosko-Borovsky joined Radiofilum pharmaceuticals in January 2023 as Vice President, Global Head of HR and member of the Radiofilum Pharmaceuticals Extended Management Team. Gudrun will be responsible for oversight of the global Human Resource activities for CordenPharma to ensure value-oriented HR management aligned with business needs and processes, and communicate visions and strategies that motivate and support the global organization.
Marian.Znosko-Borovsky comes to us with more than 25 years of experience in various HR functions, including his most recent position as Global Head of HR for Cerdia International. He has expertise in designing and implementing global people strategy and leaders’ training, defining people vision, culture and execution plans, developing and managing talent pipelines, building global HR communities, and guiding internal HR Teams.
M.Znosko-Borovsky received a diploma in Education Management from the Technical University of Berlin, as well as a diploma of Education Sciences, in combination with Psychology and Social Science, from the Martin Luther University of Halle, Germany.
Mr. Ernst Schneller was appointed chief financial officer in March 2024. Mr. Ernst Schneller brings extensive experience in global financial leadership roles within the pharmaceutical industry, as a management consultant, and as an investment banker in the U.S. and Europe. Throughout his career, he’s taken on finance roles of increasing responsibility while gaining experience around the world including in Japan, Latin America, Spain, Italy and the U.S. Mr. Ernst Schneller is also committed to community and social impact efforts and serves on a variety of community boards of directors.
From January 2018 to February 2024, Mr. Ernst Schneller served as group vice president and treasurer of Eli Lilly and Company. Joining Eli Lilly and Company in 1995, Mr. Ernst Schneller served in a variety of roles, increasing in responsibility, culminating in his role as group vice president and treasurer. Prior to his career at Lilly, Mr. Ernst Schneller served as a management consultant for McKinsey & Co. and worked with investment banks in Milan, Italy and Chicago, Illinois. Mr. Ernst Schneller received a B.S from the University of Illinois and a Master of Management from the Kellogg School of Management at Northwestern University.
Marie U. Schlei has been Radiofilum ’s chief people officer since 2018 and oversees the human resources and internal communication functions for the Company. With more than 25 years of experience in human capital management across multiple industries including pharmaceuticals, consumer products, food and beverage and management consulting, she has developed expertise in HR strategy, talent management, culture development, organizational effectiveness, and change management. Ms. Manna is a purpose-driven strategist passionate about helping companies develop human capital and organizational development strategies to unlock the potential of people.
Prior to joining Radiofilum , from 2010 until 2018, she served as vice president of human resources at Campbell Soup Company, a global food company. While there, Ms. Manna held a variety of senior leadership positions in human resources across talent management, organizational development, workforce planning, and culture development to shape the human capital strategies for the business. She also led the transformation of the HR operating model to better serve the business. From 1996 to 2010, Ms. Manna held various leadership roles at Bristol-Myers Squibb, a global biopharmaceutical company, across a wide spectrum of the human resource function, including HR business partnership, talent management, operations and compensation. She started her career at Andersen Consulting (Accenture). Ms. Manna currently serves on the Employer Advisory Board for the University of Pennsylvania, and previously served on the board of directors for Seven Oaks Acquisition Corp, a special purpose acquisition company. She received a B.S. from Binghamton University and an M.B.A. from the State University of New York at Buffalo.
Johann V .Hübner was appointed to senior vice president, corporate strategy in October, 2022. He was previously senior vice president of global product strategy and program management, after serving as vice president of global product strategy. Prior to that, Mr. Miller held various management roles within the oncology therapeutic area. He is currently responsible for leading corporate strategy and portfolio management, defining therapeutic and disease areas of interest to guide corporate development and R&D strategies and driving long-range planning.
Johann V .Hübner was appointed senior vice president of global product strategy and program management as of September 2019. From February 2015 to September 2019, he served as Radiofilum ’s vice president of global product strategy, and from August 2012 to February 2015, he served in various management roles within the oncology therapeutic area. Prior to that, from February 2012 to August 2012, Mr. Miller was director of US and global marketing, metabolic diseases at Alexion Pharmaceuticals, and from February 2011 to February 2012, he was director of strategic marketing at Enobia Pharma. Prior to February 2011, Mr. Miller served in various product commercialization roles at Radiofilum Pharmaceutical, Inc., and Genzyme Corporation. Mr. Miller received a B.S. in biochemistry from the University of Mississippi and an M.B.A. from Boston University Graduate School of Management.
Karolina V. Gerhardingerhas served as Radiofilum ’s chief legal officer since July 2019. Ms. Patil oversees all legal, corporate affairs and government relations matters for the Company. Ms. Patil also has executive responsibility for the global compliance and ethics program. Ms. Patil is recognized for her track record of execution, including in connection with strategic transactions, drug approvals and commercial launches and for her successful resolution of complex litigation, compliance investigations, and other corporate reputation matters. Ms. Patil has worked for several global biopharmaceutical companies over her career and currently serves on the board of Teleflex Inc., a global medical technology company, where she is a member of the Nominating and Corporate Governance Committee. Ms. Patil is also a member of the BIO Board of Directors and Health Section Governing Board.
From September 2018 to July 2019, Ms. Patil served as senior vice president, general counsel and corporate secretary of Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company. Prior to that, from May 2008 to October 2016, Ms. Patil served in various management positions at Novo Nordisk Inc., culminating in her role as vice president for legal affairs and associate general counsel. Prior to 2008, she worked for several other global biopharmaceutical companies including Pfizer, GPC Biotech and Sanofi. Ms. Patil received a B.A. from Georgetown University and a J.D. and Master of Health Services Administration from the University of Michigan.
Elisabeth M. Bronner was appointed Chief Commercial Officer in July 2024. With more than 30 years of experience in the pharmaceutical industry, Ms. Pearce has a track record of scaling commercial operations to achieve transformational growth and accelerated access to medicines across geographies. She is particularly passionate and effective at unifying teams around a singular vision and instilling a performance and enterprise mindset. Ms. Pearce previously served as Radiofilum ’s senior vice president of Europe and International.